Chronic beryllium disease

Sarcoidosis is a multisystem granulomatous disease of unknown cause defined by noncaseating granulomas, most commonly involving the lungs and hilar lymph nodes. Most patients are asymptomatic or have a self-limited course staged by chest radiograph; symptomatic organ-threatening disease is treated with systemic glucocorticoids, with methotrexate or another steroid-sparing agent added for glucocorticoid-refractory or glucocorticoid-intolerant disease.

Hypersensitivity pneumonitis is a mixed type III/IV immune reaction to repeated inhalation of an organic antigen in a sensitized host, producing noncaseating granulomas and bronchiolocentric inflammation. Removal of the offending antigen is the essential first step in treatment; glucocorticoids are added for significant hypoxemia or symptom burden, and unremitting exposure can progress to fibrotic lung disease indistinguishable from idiopathic pulmonary fibrosis.

Silicosis is a fibrotic occupational lung disease caused by inhaling crystalline silica dust, producing upper-zone nodular opacities and progressive dyspnea in exposed workers. Diagnosis rests on a compatible exposure history plus a characteristic imaging pattern. No agent reverses the fibrosis, so management is supportive: exposure cessation, oxygen for hypoxemia, vaccination, isoniazid prophylaxis for latent tuberculosis, and transplant evaluation for advanced disease.

Coal workers' pneumoconiosis (black lung disease) is a fibrotic dust disease of underground coal miners in which carbon-laden alveolar macrophages drive inflammation and fibrosis, producing small rounded upper-zone nodules (simple disease) that can coalesce into progressive massive fibrosis (complicated disease). Diagnosis rests on the mining history plus characteristic imaging. No drug reverses it, so management is removal from coal dust, smoking cessation, bronchodilators for coexisting obstruction, oxygen for hypoxemia, rehabilitation, and transplant referral for end-stage disease.

Asbestos-related lung disease covers a spectrum from calcified pleural plaques and benign pleural effusion to progressive asbestosis (a fibrotic interstitial lung disease) and the malignancies bronchogenic carcinoma and mesothelioma, all following inhalational asbestos exposure with latencies of 10 to 40 years. Diagnosis rests on an occupational exposure history plus imaging showing a lower-lobe usual-interstitial-pneumonia pattern or calcified pleural plaques; management of asbestosis is supportive with smoking cessation and oxygen, while mesothelioma requires pleural biopsy and multidisciplinary oncologic staging.

Tuberculosis, caused by Mycobacterium tuberculosis, remains a leading global cause of infectious death and presents as latent infection, primary/secondary pulmonary disease, or extrapulmonary and disseminated (miliary) disease. Diagnosis rests on AFB smear, NAAT, and mycobacterial culture (the gold standard), and drug-susceptible active disease is treated with a four-drug regimen (isoniazid, rifampin, pyrazinamide, ethambutol) for 2 months followed by isoniazid plus rifampin for 4 to 7 months.

Idiopathic pulmonary fibrosis is a chronic, progressive fibrosing lung disease of unknown cause defined by a usual interstitial pneumonia (UIP) pattern, presenting with progressive dyspnea, dry cough, bibasilar Velcro crackles, and clubbing in older smokers. A definite UIP pattern on high-resolution CT confirms the diagnosis without biopsy; management centers on antifibrotic therapy (pirfenidone or nintedanib), oxygen, and early lung transplant referral, since corticosteroids are not indicated and median survival is 3 to 5 years.

Interstitial lung disease (ILD), also called diffuse parenchymal lung disease, is a diverse group of nonmalignant disorders causing inflammation and scarring of the alveolar interstitium, presenting as subacute to chronic exertional dyspnea and nonproductive cough. Diagnosis rests on pulmonary function testing plus high-resolution CT pattern recognition; management is exposure removal, glucocorticoids for inflammatory disease, antifibrotic therapy for progressive fibrotic disease, oxygen for hypoxemia, and early transplant referral.

Hypercalcemia is an elevated serum calcium concentration, most often caused by primary hyperparathyroidism in ambulatory patients or malignancy in hospitalized patients. Mild disease requires only treatment of the underlying cause, while severe or symptomatic hypercalcemia is treated with aggressive IV isotonic fluids, followed by an IV bisphosphonate or denosumab for sustained control and subcutaneous calcitonin as a rapid but short-lived bridge.

Cor pulmonale is right ventricular structural and functional impairment caused by group 3 pulmonary hypertension from chronic lung disease or hypoxemia. Diagnosis rests on echocardiographic screening confirmed by right heart catheterization, and management centers on treating the underlying lung disease, correcting hypoxemia, and cautious diuresis.

Lung cancer is the leading cause of cancer death worldwide, split into non-small cell lung cancer (NSCLC, 80% of cases: adenocarcinoma, squamous cell, large cell) and small cell lung cancer (SCLC, 10-15%), both driven overwhelmingly by cigarette smoking. Diagnosis requires tissue histopathology, staging drives treatment (TNM staging for NSCLC, limited versus extensive stage for SCLC), and management ranges from lobectomy in early-stage disease through concurrent chemoradiation and consolidation immunotherapy in locally advanced disease to targeted tyrosine kinase inhibitors, immune checkpoint inhibitors, or platinum-based chemotherapy in metastatic disease.